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ABSTRACT
A single-institution, open-label prospective pharmacokinetic evaluation of the interaction between intravenous
itraconazole and intravenous cyclosporin A and tacrolimus was conducted in allogeneic hematopoietic stem cell
transplant recipients. The study was conducted in 2 phases, with patients acting as their own controls. In phase
1, steady-state concentrations and clearance of cyclosporin A and tacrolimus administered alone were evalu-
ated. Phase 2 evaluated serum concentrations and clearance of cyclosporin A and tacrolimus under the
influence of itraconazole therapy. Among 17 patients who completed both phases of the study, the mean
increase in the serum tacrolimus concentration was 83% (P < .0001), and the mean increase in the serum
cyclosporin A concentration was 80% (P  .0001). There was no correlation between serum itraconazole
concentrations and the serum concentrations of tacrolimus or cyclosporin A. The drug interaction between
itraconazole and calcineurin inhibitors is predictable and occurs within 48 hours of concomitant drug admin-
istration. The data suggest that dose reductions of tacrolimus and cyclosporin A in the range of 50% to 100%
are necessary when itraconazole therapy is initiated and that subsequent close monitoring of serum concen-
trations is necessary to guide further dose modifications.
© 2006 American Society for Blood and Marrow Transplantation
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gNTRODUCTION
Patients undergoing hematopoietic stem cell trans-
lantation (HSCT) are at risk of developing bacterial,
iral, and fungal infections as a consequence of immu-
osuppression and prolonged marrow suppression
rom cytotoxic chemotherapy in the preparative regi-
en. Similarly, posttransplantation immunosuppres-
ion to prevent the development of, as well as to treat,
raft-versus-host disease increases the susceptibility to
uch infections.
Superﬁcial and systemic fungal infections are im-
ortant causes of morbidity and mortality in immu- a
B&MTocompromised patients despite the aggressive use of
ntifungal agents. Administration of systemically avail-
ble azole antifungal agents as part of the prophylactic
trategy in this population has resulted in signiﬁcant
eductions in the number of systemic fungal infections
1-8], superﬁcial fungal infections [2,7], fungal colo-
ization [2], and the empiric use of amphotericin B
1,2,7]. The current Centers for Disease Control/
nfectious Disease Society of America/American So-
iety of Blood and Marrow Transplantation consensus
uidelines for preventing opportunistic infections
mong HSCT recipients recommend routine use of ﬂu-
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3onazole in HSCT recipients from day 0 until engraft-
ent [9]. Fluconazole, although highly effective against
andida albicans, is ineffective against mold pathogens
uch as Aspergillus species that are being increasingly
escribed in HSCT recipients [10]. Itraconazole, an-
ther triazole, has demonstrated a broader spectrum
f activity against a wide variety of Candida and As-
ergillus species [11-13].
The widespread use of itraconazole was limited in
he past because of the lack of a formulation that
rovides reliable serum concentrations. Published data
uggest that protection against Aspergillus species is
est achieved with serum itraconazole concentrations
500 ng/mL [8,14]. The availability of both an oral
olution (much improved bioavailability) and an intra-
enous (IV) formulation makes the attainment of tar-
et serum concentrations much more reliable. Recent
ata suggest a protective effect of itraconazole against
nvasive mold infections when used prophylactically in
SCT recipients [15,16] and in patients with hema-
ologic malignancies [8]. Although it offers a broader
pectrum of antifungal activity, itraconazole has sev-
ral potential drug interactions in HSCT patients.
traconazole is a potent inhibitor of the cytochrome
450 (CYP) 3A4 isoenzyme system, a common met-
bolic pathway for many medications. One of the most
mportant interactions requiring consideration is that
etween itraconazole and the calcineurin inhibitors
yclosporin A and tacrolimus.
There are several published reports outlining a
otential drug interaction between cyclosporin A and
traconazole in solid organ transplant recipients and
SCT recipients [17-24]. Increases in cyclosporin A
erum concentrations ranged from 40% to 226% and
ften resulted in increases in serum creatinine. Simi-
arly, several case reports/case series demonstrate a
rug interaction between tacrolimus and itraconazole,
ith increases in serum tacrolimus concentrations up
o 6.6-fold [19,25-31]. All of these reports involve the
nteraction between oral itraconazole and oral cal-
ineurin inhibitors. An evaluation of the pharmacoki-
etic drug interaction between IV itraconazole and IV
yclosporin A/tacrolimus has not been reported. It can
e hypothesized that the drug interaction would be
imilar despite differences in the route of administra-
ion, but this cannot be assumed. Earlier work char-
cterizing the pharmacokinetic drug interaction be-
ween IV ﬂuconazole and IV cyclosporin A/tacrolimus
ailed to demonstrate a clinically meaningful increase
n serum cyclosporin A/tacrolimus concentrations
32], despite numerous case reports in the literature
emonstrating a drug interaction when ﬂuconazole
nd calcineurin inhibitors were administered orally
33-35]. We therefore conducted an open-label, pro-
pective evaluation of the pharmacokinetic drug inter-
ction between IV itraconazole and IV cyclosporin A
nd IV tacrolimus. t
26ETHODS
tudy Design
A single-institution, open-label, prospective com-
arative pharmacokinetic study was performed from
une 2000 to February 2002.
tudy Population
Twenty-seven allogeneic (sibling and matched un-
elated donor) HSCT recipients participated in a
ithin-subject pharmacokinetic study to determine
he effect of IV itraconazole on the pharmacokinetic
roﬁle of IV administered calcineurin inhibitors (cy-
losporin A and tacrolimus). This study had the ap-
roval of the Institutional Review Board of the Uni-
ersity of Florida, and voluntary, written, informed
onsent was obtained before any study procedures
ere undertaken. The US Department of Health and
uman Services guidelines for human experimenta-
ion were followed in the conduct of this clinical
esearch.
Men and women were enrolled in the study if they
ere eligible for an allogeneic (sibling or matched
nrelated donor) HSCT protocol, were at least 18
ears old, were receiving tacrolimus at the same dose
or at least 60 hours before both pharmacokinetic
valuations or cyclosporin A at the same dose for at
east 95 hours before both pharmacokinetic evalua-
ions, were not being treated with medications that
ight affect hepatic CYP function, and had either
acrolimus blood concentrations of 5 to 15 ng/mL or
yclosporin A blood concentrations of 150 to 225
g/mL before entry onto this study. To complete the
tudy, patients had to have stable renal and hepatic
unction throughout both phases. Subject characteris-
ics are summarized in Table 1. Patients were ex-
luded from this study if they displayed unstable or
mpaired renal function, if they demonstrated evi-
ence of an active fungal infection, if they were re-
eiving other systemic prophylactic azole antifungal
herapy within 7 days of study entry, or if they were
eceiving any drugs known to interact with the cal-
ineurin inhibitors by induction or inhibition of the
YP3A4 isoenzyme system.
Upon determination of study eligibility, patients
ndergoing an allogeneic HSCT, either from a sibling
r a matched unrelated donor, received either (1)
acrolimus administered as a continuous infusion (0.03
g/kg ideal body weight per day) from the day before
SCT (day 1) until engraftment or (2) cyclosporin
1.5 mg/kg (ideal body weight) IV as a 3-hour infu-
ion every 12 hours from the day before HSCT until
ngraftment. Itraconazole injection at a dose of 200
g IV every 12 hours for 2 days, followed by 200 mg
V daily, was initiated once steady state was achieved
ith either tacrolimus or cyclosporin A and the pa-
ients exhibited stable tacrolimus/cyclosporin A blood
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Pharmacokinetic Drug Interaction between Itraconazole and Calcineurin Inhibitors
Bevels. All medications were administered IV through
he transplantation course until granulocyte recovery
absolute neutrophil count 250/L) or improve-
ent of mucositis to World Health Organization
rade I/II.
This study involved 2 separate phases, and each
atient acted as his or her own control. In phase 1,
able 1. Characteristics of Patients Enrolled in a Study of the
harmacokinetic Interaction between Intravenous Itraconazole and
ntravenous Tacrolimus and Intravenous Cyclosporine
Characteristic
Tacrolimus
Recipients
(n  9)
Cyclosporine
Recipients
(n  8)
ge, y, mean (range) 40.3 (21-64) 41.3 (19-61)
ex
Male 5 4
Female 4 4
nderlying disease
AMLRel 1 0
AML CR1 2 0
AML CR2 3 0
CLLRel 0 1
CML CP2 1 0
MM CR1 0 2
MM PD 0 1
MM SD 1 0
MLL CR1 0 1
MDS 0 1
NHLRel with progression 1 1
NHL CR3 0 1
ransplant type
Allogeneic (sibling) 0 5
Allogeneic (matched
unrelated donor) 5 1
Nonmyeloablative
allogeneic sibling 3 2
Nonmyeloablative matched
unrelated donor 1 0
reparative regimen
Busulfan/cyclophosphamide 0 1
Busulfan/cyclophosphamide/
etoposide 0 4
Busulfan/fludarabine/
ATGAM 4 0
Cyclophosphamide/total
body irradiation 5 1
Etoposide/total body
irradiation 0 1
Fludarabine/total body
irradiation 0 1
erum creatinine (baseline),
median (mg/dL) 0.8 (0.7-1) 0.7 (0.5-1.3)
ilirubin (before therapy),
median (U/L) 0.3 (<0.2-0.8) 0.5 (0.2-0.9)
ST, median (U/L) 24 (13-37) 20-23 (15-36)
LT, median (U/L) 39 (12-86) 23 or 29 (19-66)
ML indicates acute myeloid leukemia; Rel, relapsed; CR, complete
remission; CLL, chronic lymphocytic leukemia; CP, chronic
phase; MM, multiple myeloma; PD, progressive disease; SD, stable
disease; MLL, mixed lineage leukemia; MDS, myelodysplastic
syndrome; NHL, non-Hodgkin lymphoma; ATGAM, antithy-
mocyte -globulin; AST, aspartate aminotransferase; ALT, ala-
nine aminotransferase.nce patients were at steady state and demonstrated a
B&MTtable tacrolimus/cyclosporin A dosing, daily serum
acrolimus/cyclosporin A concentrations were col-
ected. The mean of 2 stable steady-state blood levels
as used in the calculation of clearance. Upon com-
letion of this phase, IV itraconazole therapy was
nitiated. Once steady state with itraconazole was
chieved (approximately 2 days), daily blood samples
ere drawn to measure tacrolimus/cyclosporin A se-
um concentrations under the inﬂuence of itracon-
zole. The mean of 4 consecutive days of stable
teady-state blood concentrations was used to calcu-
ate clearance. Itraconazole and hydroxy-itraconazole
evels were monitored daily after the attainment of
teady state.
Serum creatinine was monitored daily, and liver
unction tests were monitored 3 times a week for the
uration of the study. Concomitant medications that
ould potentially interact with tacrolimus or cyclo-
porin A were recorded.
rug Sampling
On pharmacokinetic study days, whole-blood
amples (5 mL) were obtained through the central line
r via venipuncture and drawn into Vacutainer tubes
Becton Dickinson, Franklin Lakes, NJ) immediately
efore dosing. The cyclosporine whole-blood assay
as used to quantitate the cyclosporin A concentra-
ion by using the ﬂuorescence polarization immuno-
ssay technology previously described. Once col-
ected, samples were centrifuged in the laboratory at
500g for 5 minutes and assayed by using standard
ethodology. Tacrolimus serum concentrations were
uantiﬁed by using the Imx Tacrolimus II assay (Ab-
ott Diagnostics, Abbott Park, IL) with microparticu-
ate enzyme immunoassay technology. Trough blood
amples for itraconazole were collected into a red-top
ube, and the specimen was allowed to clot for 60
inutes. The serum was separated from the clot by
entrifugation (3000 rpm for 10 minutes). The serum
as removed by pipette into cryovials and frozen at
80°C. Samples were batched and sent frozen on dry
ce to the Fungus Testing Laboratory in San Antonio,
X, for analysis.
traconazole Assay
Serum concentrations of itraconazole and hy-
roxy-itraconazole were assayed with a previously de-
cribed modiﬁed and validated reverse-phase high-
erformance liquid chromatography method [36].
harmacokinetic Analysis
Steady-state concentrations and clearance were
ompared between tacrolimus/cyclosporin A alone and
acrolimus or cyclosporin A with concomitant itracon-
zole.
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3Clearance was calculated with the following for-
ula:
Dose ng/1440 min
Tacrolimus or cyclosporin A level ng/mL IBW kg
mL/min/kg
tatistical Analysis
The change in tacrolimus or cyclosporin A con-
entrations and clearance with and without concomi-
ant itraconazole was evaluated by using the paired
ifference t test after the Shapiro-Wilk test results
emonstrated that the normality assumptions were
atisﬁed. A change was considered to be statistically
igniﬁcant if the P value was .05. A clinically mean-
ngful change was predetermined to be 35% to 100%.
he correlation between mean steady-state concen-
rations of itraconazole or hydroxyitraconazole with
ither tacrolimus or cyclosporin A was evaluated by
sing the Pearson correlation after the Shapiro-Wilk
est results demonstrated that the normality assump-
ions were satisﬁed.
ESULTS
tudy Participants
Twenty-seven patients were enrolled in this trial,
nd 17 successfully completed both phases of the
tudy. Of the 10 patients who did not complete both
hases, 2 were changed to alternate antifungal therapy
1 patient developed oral thrush before the initiation
f itraconazole; 1 patient was switched to conventional
mphotericin B for persistent fever), 3 were unable to
chieve stable serum concentrations of cyclosporin
/tacrolimus within the allocated time, 1 patient de-
eloped renal dysfunction (due to sepsis from gram-
ositive bacteremia), 1 patient had elevated liver func-
ion tests at the completion of phase 1 before the
nitiation of itraconazole therapy, 1 patient developed
ertigo during each itraconazole infusion and asked to
e withdrawn, and 2 patients were protocol violations.
herefore, 17 patients were eligible for evaluation: 9
atients receiving tacrolimus and 8 patients receiving
able 2. Mean Trough Plasma Concentrations of Itraconazole and the
Treatment Day Patients (n)
Plasma Con
Itraconazole
3 17 0.541  0.32
4 17 0.586  0.30
5 17 0.689  0.36
6 17 0.710  0.36yclosporin A. 8
28traconazole Serum Levels
At the completion of the itraconazole loading
ose (200 mg IV every 12 hours for 4 doses), the
ean steady-state concentration was 0.541  0.326
g/mL (median, 0.430 ng/mL; range, 0.136-1.214
g/mL) for all 17 patients. At this time, 88.2% of pa-
ients achieved an itraconazole serum concentration of
250 ng/mL, and 35.3% achieved an itraconazole se-
um concentration of500 ng/mL. Repeat itraconazole
oncentrations on the last day of the pharmacokinetic
nalysis resulted in 88.2% of patients achieving a serum
traconazole concentration 250 ng/mL and 70.6%
chieving a serum itraconazole concentration 500 ng/
L. The mean serum itraconazole and hydroxyitracon-
zole concentrations achieved over time are shown in
able 2.
yclosporin A/Tacrolimus Serum Levels
The mean daily steady-state tacrolimus concen-
rations ranged from 7.6 to 12.75 ng/mL before the
nitiation of itraconazole and ranged from 16.65 to
2.52 ng/mL after the initiation of itraconazole
herapy. The second set of serum concentration
stimates was obtained starting 2 days after the
nitiation of IV itraconazole therapy. The mean of 4
ays of serum concentration estimates was calcu-
ated. The mean daily steady-state cyclosporin A
oncentration ranged from 101.5 to 216 ng/mL
efore the initiation of itraconazole and ranged
rom 226.25 to 298.5 ng/mL after the initiation of
traconazole therapy, as previously described. The
aily distribution of the immunosuppressant levels
s illustrated in box plots in Figures 1 and 2. The
ean steady-state tacrolimus concentration (for all
atients receiving tacrolimus) without itraconazole
as 10.37 ng/mL and increased to 18.97 ng/mL
fter the addition of itraconazole. This corresponds
o an 83% increase in the tacrolimus serum concen-
ration (P  .0001). The mean steady-state cyclo-
porin A concentration without itraconazole was
51.18 ng/mL and increased to 272.18 ng/mL after
he addition of itraconazole; this is an increase of
lite Hydroxyitraconazole
tion, ng/mL (mean  SD)
% Patients with a Serum
Itraconazole Level
>250/500 ng/mLHydroxyitraconazole
1.021  0.371 88.2/35.3
1.103  0.425 88.2/41.2
1.216  0.452 88.2/64.7
1.259  0.469 88.2/70.5Metabo
centra
6
7
90% (P  .0001).
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Pharmacokinetic Drug Interaction between Itraconazole and Calcineurin Inhibitors
Borrelation between Itraconazole Levels
nd Changes in Serum Concentrations
f Calcineurin Inhibitors
The association between mean steady-state itra-
onazole with either tacrolimus or cyclosporin A con-
entrations, by using Pearson correlation coefﬁcients,
as not signiﬁcant (tacrolimus: R  0.532, P  .14;
yclosporine, R  0.189, P  .65). Associations
etween the mean steady-state hydroxyitraconazole
ith either tacrolimus or cyclosporin A concentrations
as also not signiﬁcant (tacrolimus: R  0.518, P 
15; cyclosporine, R  0.048, P  .91).
ose Modifications of Calcineurin Inhibitors
Among tacrolimus recipients, 1 patient (11.1%)
equired a 20% increase in the dose of tacrolimus, and
patients required no dosage modiﬁcations. Five pa-
ients (55.5%) required tacrolimus dose reductions.
hese reductions ranged from 20% to 76.5%. Among
yclosporin A recipients, 62.5% of patients required
o dosage modiﬁcations, and 37.5% required cyclo-
porin A dose reductions that ranged from 24.4% to
1.1%.
oxicity and Clinical Outcome
Two patients had a documented adverse event
ttributable to itraconazole therapy. One patient de-
eloped renal dysfunction as a consequence of sus-
ained increased serum concentrations of tacrolimus,
nd 1 patient experienced a burning sensation during
ach infusion of itraconazole, although treatment was
ot stopped for this event. Four patients (23.5%) had
traconazole therapy changed to alternative antifungal
herapy (2 patients changed to conventional ampho-
ericin B, 1 patient changed to amphotericin B lipid
omplex, and 1 patient had conventional amphotericin
added to itraconazole therapy), although each pa-
ient completed both phases of the study before anti-
igure 1. Tacrolimus serum concentration versus time (days) curve
rom the start of itraconazole therapy.ungal modiﬁcation. c
B&MTThe median baseline serum creatinine level was
.7 mg/dL (range, 0.5-1.3 mg/dL), which increased to
median peak serum creatinine level of 0.9 mg/dL
range, 0.4-1.5 mg/dL) during treatment with itracon-
zole and cyclosporin A/ tacrolimus and remained at
his value at the end of itraconazole therapy. The
edian peak bilirubin level during concomitant itra-
onazole and cyclosporin A/tacrolimus therapy was
.9 mg/dL (range, 0.3-4.6 mg/dL), and this declined
o 0.7 mg/dL at the end of itraconazole therapy
range, 0.2-5.1 mg/dL).
Among our study participants, the increases in
erum concentrations of cyclosporin A and tacrolimus
ere relatively consistent. To explore whether or not
henytoin, given to patients receiving busulfan-con-
aining preparative regimens, may have affected the
nteraction, we compared the results in recipients re-
eiving phenytoin seizure prophylaxis (n  9) with
hose in patients who were not receiving seizure pro-
hylaxis (n 8) within each group. Among patients in
he tacrolimus group, there was no signiﬁcant differ-
nce in the magnitude of the interaction between
henytoin and nonphenytoin recipients. Similarly, in
he cyclosporin A group, there was no signiﬁcant dif-
erence between the phenytoin and nonphenytoin
roup and the effect on increases in serum concentra-
ions of cyclosporin A.
ISCUSSION
Azole antifungals differ not only in their spectrum
f activity, but also in their metabolic pathways. These
rugs are metabolized by the CYP isoenzyme system,
he subfamily of CYP enzymes that seem to be re-
ponsible for the metabolism of the widest range of
rugs and exogenous compounds in humans. Drugs
hat require metabolism by the same CYP enzymes
ompete for binding to and metabolism by CYP.
igure 2. Cyclosporin A serum concentration versus time (days)
urve from the start of itraconazole therapy.
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3herefore, in theory, any 2 drugs that are metabolized
y identical CYP isoenzymes have a potential for
nteraction; however, the clinical signiﬁcance of this
nteraction will rely on the drugs’ relative afﬁnities for
inding to these enzymes, concentrations achieved in
he endoplasmic reticulum after therapeutic doses,
ependence on CYP for elimination, and therapeutic
atios [37,38]. Fluconazole, the azole used extensively
s prophylaxis against Candida species infections in
SCT recipients, inhibits and is metabolized by the
YP isoenzymes. Fluconazole is not a potent inhibitor
f CYP3A4 isoenzymes at lower doses (200 mg/d),
ut at higher doses it can inhibit CYP3A4. Itracon-
zole is also capable of inhibiting and being metabo-
ized by CYP3A4 isoenzymes. Itraconazole is a far
ore potent inhibitor of the CYP3A4 isoenzymes
nd, as a consequence, may result in more drug inter-
ctions, as well as a greater magnitude when an inter-
ction occurs.
Tacrolimus and cyclosporin A are primarily me-
abolized by CYP3A4 isoenzymes. The CYP3A4 iso-
nzymes are the most abundant isoforms of CYP,
ccounting for nearly 30% of the total CYP content in
he human liver and as much as 70% in the gut wall.
herefore, there is a potential for major drug inter-
ctions between itraconazole, a potent inhibitor of
YP3A4, and cyclosporin A and tacrolimus. It has
een postulated that tacrolimus and cyclosporin A are
lso metabolized in the intestine by CYP 3A4 isoen-
ymes. If this does occur, it might explain why a drug
nteraction is seen with other azoles and tacrolimus or
yclosporine when administered orally and not when
dministered IV.
Earlier drug interaction research with ﬂuconazole
nd tacrolimus/cyclosporin A yielded conﬂicting results
occurrence and magnitude) depending on the route of
dministration [32-35]. Numerous case reports demon-
trated an interaction between oral ﬂuconazole and oral
acrolimus/cyclosporin A. Osowski et al. [32] evaluated
he drug interaction between IV ﬂuconazole and IV
acrolimus/cyclosporin A in HSCT recipients. When
dministered IV, there was no statistically or clinically
igniﬁcant difference in the steady-state concentra-
ions of tacrolimus and a statistically, but not clini-
ally, signiﬁcant increase (21%) in the serum cyclo-
porin A concentration.
These are considerable differences between the
zole antifungals in their metabolic pathways, target
YP isoenzymes, and ability to inhibit CYP3A4
soenzymes. This study was able to clearly character-
ze the pharmacokinetic drug interaction between IV
traconazole and IV tacrolimus/cyclosporin A. In this
ontrolled pharmacokinetic study, we documented in-
reases in mean steady-state serum concentrations of
yclosporin A and tacrolimus in all study subjects. The
ean steady-state increase in the serum concentration
f cyclosporin A and tacrolimus was 80% and 83%, r
30espectively; however, there was considerable variabil-
ty in the magnitude of the increase. Among patients
ho received cyclosporin A and itraconazole, the in-
rease in serum cyclosporin A concentrations ranged
rom 24% to 149%. Similarly, tacrolimus recipients
xperienced increases in serum concentrations rang-
ng from 49% to 117%. The onset of the increase in
erum concentration occurred within 48 to 72 hours
f the initiation of IV itraconazole. These data suggest
hat a reduction in cyclosporin A and tacrolimus in the
ange of 50% to 100% is needed and that this reduc-
ion would be advisable at the time of initiation of
traconazole. Because of the considerable variability in
he magnitude of increase seen, no precise dose mod-
ﬁcation is likely to precisely achieve the desired blood
oncentration. One should weigh the relative risks of
ephrotoxicity (from excessive calcineurin inhibitor
xposure) and graft-versus-host disease (from low
oncentrations of calcineurin inhibitors) in judging
he best dose reduction for a given patient.
Future studies could prospectively evaluate the
ffect of a prespeciﬁed dose reduction. There are
everal reports in the medical literature that describe
n interaction between oral cyclosporin A and oral
traconazole and between oral tacrolimus and oral
traconazole. Most of the data for cyclosporin A arise
rom case reports in solid organ transplant candidates
nd are summarized in Table 3. The magnitude of the
ncrease in serum cyclosporin A concentration varied,
nd this may be a result of different doses of itracon-
zole. Among these reports, the increase in serum
yclosporin A concentrations ranged from 40% to
26%, with reductions in doses of 33% to 84% [17-
4]. In several case reports, there was associated im-
airment of renal function. In 2 studies in which
traconazole, cyclosporin A, and 3-hydroxy-3-methyl-
lutaryl-coenzyme A–reductase inhibitors were ad-
inistered, rhabdomyolysis resulted [21,22]. The
agnitude of the interaction seen with oral itracon-
zole and oral cyclosporin A is comparable to the
agnitude of the interaction we have described with
oth agents administered IV.
Similarly, several case reports and case series char-
cterize a drug interaction between oral tacrolimus
nd oral itraconazole, and these are summarized in
able 4. Serum concentrations of tacrolimus in-
reased from 2- to 6.6-fold [25,27,28], thus necessi-
ating dose reductions of 45% to 75% [18,25,26,29-
1]. In 1 case report, the addition of 400 mg of oral
traconazole to a kidney transplant recipient receiving
mg of tacrolimus daily resulted in a 14-fold dose
eduction, to a daily maintenance dose of 0.4 mg [28].
he magnitude of these reported interactions varies
onsiderably, and the cause of this remains unknown
ecause of the nature of the reports. Our data with IV
acrolimus and IV itraconazole are comparable to the
esults seen with oral administration.
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Pharmacokinetic Drug Interaction between Itraconazole and Calcineurin Inhibitors
BTherefore, the pharmacokinetic drug interaction
etween IV itraconazole and IV tacrolimus/cyclo-
porin A differs considerably from the drug interac-
ion between IV ﬂuconazole and IV tacrolimus/cyclo-
porin A. A drug interaction that is clinically and
tatistically signiﬁcant occurs between IV itraconazole
nd IV tacrolimus/cyclosporin A. The magnitude is
imilar to that reported with oral administration in
umerous case reports, case series, and small pharma-
okinetic analyses [17-31].
When designing this pharmacokinetic interaction
tudy, we made an assumption, based on data from the
anufacturer, that steady-state concentrations of itra-
onazole are achieved after the completion of the
oading dose of IV itraconazole. We measured the
oncentrations of itraconazole and its metabolite hy-
roxyitraconazole from baseline through the comple-
ion of the pharmacokinetic analysis. Itraconazole and
ydroxyitraconazole serum concentrations varied con-
iderably from subject to subject. Upon analysis of the
esults, it is clear that adequate concentrations required
o “prevent” an aspergillus infection were not achieved
ithin that time frame in most patients. The literature
uggests that serum itraconazole concentrations of
500 ng/mL are required to prevent Aspergillus spe-
ies infections [1,8,14,39]. At the completion of the
oading dose, only 33% of patients had achieved this
arget concentration, and by the end of the pharma-
okinetic analysis (at least 72 hours later), the propor-
ion of patients who achieved this concentration in-
reased to 71%. This suggests that steady state is not
chieved after the completion of the loading dose and
hat it takes a further 72 hours to reach steady state.
These results differ from earlier clinical trial data
n which the mean serum concentrations of itracon-
zole and hydroxyitraconazole at the conclusions of
he loading dose were higher [40,41]. Although the
ean concentration of itraconazole achieved in our
linical trial was within the therapeutic range for max-
mal protection against developing an aspergillus in-
ection, further analysis of the proportion of patients
ith a serum itraconazole concentration of 250 or
500 ng/mL demonstrated a low percentage of pa-
ients at the required “protective” concentrations.
arlier clinical trials did not provide a breakdown of
atients who achieved a serum concentration 500
g/mL, thus making comparisons between the pub-
ished literature and our study difﬁcult. Few patients
n this pharmacokinetic trial achieved serum itracon-
zole concentrations 500 ng/mL after the loading
ose, and this suggests that the current dose is insuf-
cient to rapidly obtain a therapeutic concentration.
linicians should not anticipate that most patients will
e within the therapeutic range for 5 to 7 days.
We performed an analysis to determine whether
here was any effect of serum itraconazole and hy-
droxyitraconazole concentrations on the magnitude ofTa Kw Kr
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Table 4. Literature Reports Characterizing a Drug Interaction between Itraconazole and Tacrolimus
Authors No./Transplant Type Data Type
Dose and Route of
Tacrolimus Administered
(before Interaction)
Dose of Itraconazole and
Route of Administration Results Toxicity
Kramer et al. [19]
10 (7 CyA; 4 FK)/lung (9),
heart-lung (1) Case series Not stated 100 mg PO BID  3 mo
2 FK dose 65%;
2 Daily cost of FK by 48% Not stated
Ideura et al. [25] 1/kidney Case report
0.14 mg/kg PO QD
(2 to 0.035 mg/kg) 100 mg PO QD
1 [FK] 2-fold
2 FK dose 75%
1 SCr (not rejection, biopsy
proven)
Outeda Macias et al. [26] 1/kidney Case report 0.1 mg/kg/d PO Dose not stated
1 [FK] ¡ 2 FK dose of
75% 1 BUN; 1 SCr
Furlan et al. [27] 1/heart-lung Case report 0.085 mg/kg PO Dose not stated 1 [FK] 3-fold 1 SCr
Banerjee et al. [29]
28/lung (9); double-lung (7);
heart-lung (9); heart (3) Case series 8.4 mg/d (mean dose) 100 mg PO BID
2 FK dose 45-75%*
78% had supratherapeutic
levels†
No significant changes in
SCr or LFTs
2 Daily cost by 62%
Cervelli and Russ [28] 1/kidney Case report 4 mg QAM/3 mg QPM PO 400 mg PO QHS
1 [FK] 6.6-fold
2 FK dose from 7 mg to
0.4 mg/d Not stated
Capone et al. [30] 1/kidney Case report 6 mg PO QD 100 mg PO BID  5 d 2 FK dose by 50% 1 SCr
Mahnke et al. [31]
22/heart (2); heart-lung (9);
lung (11) Case series 0.27 mg/kg/d PO Not stated 2 FK requirements by 68% Not stated
PO indicates oral; BID, twice daily; 2, decrease; CyA, cyclosporin A; QD, once daily; QAM, every morning; QPM, every night; QHS, at bedtime; BUN, blood urea nitrogen; FK, tacrolimus; [FK],
tacrolimus serum concentration; SCr, serum creatinine; ¡, leading to; LFTs, liver function tests.
*Age-dependent increases, where older patients had a greater magnitude of dose reduction.
†When itraconazole was discontinued, the mean dose increase of tacrolimus was 87%.
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Pharmacokinetic Drug Interaction between Itraconazole and Calcineurin Inhibitors
Bhe interaction with cyclosporin A or tacrolimus (data
ot shown). No such correlation existed.
In conclusion, in a controlled pharmacokinetic
tudy, we have demonstrated that there is a signiﬁcant
nteraction between IV itraconazole and IV cyclo-
porin A, as well as between IV itraconazole and IV
acrolimus. This interaction is predictable, occurring
ithin 48 hours of concomitant administration.Whereas
he mean increases in the serum concentrations of cy-
losporin A and tacrolimus are similar, there was con-
iderable variability within each group in terms of the
agnitude of the increase. The magnitude of the dose
odiﬁcation will be dependent on the initial serum
oncentration of the calcineurin inhibitor and the ﬁnal
arget concentration. A recent publication evaluating
he oral drug interaction between itraconazole and
alcineurin inhibitors has demonstrated that an em-
irical dose reduction of the calcineurin inhibitor of
0% should occur when itraconazole is added (or the
ay before, if possible) [31]. Further dose reductions
f 20% to 25% may be necessary 4 to 7 days after the
ddition of itraconazole. This will reduce the likeli-
ood of wide ﬂuctuations in tacrolimus and cyclo-
porin A concentrations and will reduce toxicity.
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